Matinas BioPharma Holdings, Inc. (MTNB)Healthcare | Biotechnology | Bedminster, United States | NYSE American
2.74 USD
-0.13
(-4.530%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:26 a.m. EDT
The immediate outlook is severely compromised by a catastrophic collapse in share price, which has erased approximately 90% of the company's value over the trailing twelve months. This massive drawdown, coupled with a current trading price far below the 50-day and 200-day moving averages, indicates a market that has aggressively priced out the current reality. The business fundamentals are equally dire, characterized by significant losses, negative cash flow, and a negative return on equity, leaving no cushion against further volatility. While a strategic combination with GH Power offers a potential path forward, the execution risk remains extreme given the depleted capital base and the sheer magnitude of the prior decline. There is no dividend to provide income, and the statistical models lack the data reliability to offer any short-term trading edge. Investors should view this as a highly speculative gamble on a turnaround rather than a viable investment opportunity. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.333 |
| Market Cap | 2,683,884 |
| Forward P/E | -0.91 |
| Beta | 2.08 |
| Website | https://www.matinasbiopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9038597 |
| Address1 | 1,545 Route 206 South |
| Address2 | Suite 302 |
| All Time High | 2,992.5 |
| All Time Low | 2.265 |
| Ask | 2.8 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 221,440 |
| Average Daily Volume3 Month | 394,413 |
| Average Volume | 394,413 |
| Average Volume10Days | 221,440 |
| Beta | 2.08 |
| Bid | 2.62 |
| Bid Size | 100 |
| Book Value | 4.215 |
| City | Bedminster |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.74 |
| Current Ratio | 0.847 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.79 |
| Day Low | 2.7 |
| Debt To Equity | 0.333 |
| Display Name | Matinas BioPharma |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,723,667,400 |
| Earnings Call Timestamp Start | 1,723,667,400 |
| Earnings Timestamp End | 1,755,115,200 |
| Earnings Timestamp Start | 1,755,115,200 |
| Ebitda | -6,662,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.29 |
| Enterprise Value | 1,928,884 |
| Eps Forward | -3.0 |
| Eps Trailing Twelve Months | -17.55 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0315 |
| Fifty Day Average Change | -0.2915001 |
| Fifty Day Average Change Percent | -0.096157044 |
| Fifty Two Week Change Percent | -90.38597 |
| Fifty Two Week High | 28.95 |
| Fifty Two Week High Change | -26.210001 |
| Fifty Two Week High Change Percent | -0.9053541 |
| Fifty Two Week Low | 2.265 |
| Fifty Two Week Low Change | 0.4749999 |
| Fifty Two Week Low Change Percent | 0.20971297 |
| Fifty Two Week Range | 2.265 - 28.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,405,949,400,000 |
| Float Shares | 763,075 |
| Forward Eps | -3.0 |
| Forward P E | -0.91333336 |
| Free Cashflow | -2,448,500 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 2 |
| Fullday Change | -0.13000011 |
| Fullday Change Percent | -4.727277 |
| Fullday Price | 2.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23752001 |
| Held Percent Institutions | 0.022119999 |
| Implied Shares Outstanding | 979,520 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,790,553,600 |
| Last Split Factor | 1:15 |
| Long Business Summary | Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey. |
| Long Name | Matinas BioPharma Holdings, Inc. |
| Market | us_market |
| Market Cap | 2,683,884 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_243651290 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -7,309,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,571,239 |
| Open | 2.85 |
| Operating Cashflow | -6,420,000 |
| Operating Margins | 0.0 |
| Phone | 908 484 8805 |
| Pre Market Change | -0.13000011 |
| Pre Market Change Percent | -4.727277 |
| Pre Market Price | 2.62 |
| Pre Market Time | 1,791,894,069 |
| Previous Close | 2.87 |
| Price Hint | 4 |
| Price To Book | 0.6500593 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.564 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.13 |
| Regular Market Change Percent | -4.52961 |
| Regular Market Day High | 2.79 |
| Regular Market Day Low | 2.7 |
| Regular Market Day Range | 2.7 - 2.79 |
| Regular Market Open | 2.85 |
| Regular Market Previous Close | 2.87 |
| Regular Market Price | 2.74 |
| Regular Market Time | 1,791,835,200 |
| Regular Market Volume | 18,137 |
| Return On Assets | -0.56172 |
| Return On Equity | -1.41235 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 979,520 |
| Shares Percent Shares Out | 0.0573 |
| Shares Short | 56,158 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 20,749 |
| Short Name | Matinas Biopharma Holdings, Inc |
| Short Percent Of Float | 0.0574 |
| Short Ratio | 0.62 |
| Source Interval | 15 |
| State | NJ |
| Symbol | MTNB |
| Total Cash | 761,000 |
| Total Cash Per Share | 0.777 |
| Total Debt | 6,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -17.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.54305 |
| Two Hundred Day Average Change | -4.80305 |
| Two Hundred Day Average Change Percent | -0.6367517 |
| Type Disp | Equity |
| Volume | 18,137 |
| Website | https://www.matinasbiopharma.com |
| Zip | 7,921 |